Kineta acquisition closed; Q1 2025 financials show $1.7M net loss and $13.2M deficit

TuHURA Biosciences, Inc./NV

Cash $304K, total liabilities $14M, stockholders' deficit $13.2M as of March 31, 2025.
Net loss attributable to Kineta for Q1 2025 was $1.676M vs $10.238M in Q1 2024 on reduced R&D spend.
Accumulated deficit reached $184.6M; Kineta has going concern warning with insufficient cash for next 12 months.
Merger consideration includes up to $16.5M initial stock, $6.5M delayed stock, $12M cash (net of exclusivity credits and working capital adjustments).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.